COVID Vaccine: FDA Committee Advises Dosage of Pfizer to Children 5-11 Years

An advisory committee to the United States Food and Drug Administration (FDA) recommended on Tuesday the approval for emergency use of Pfizer’s covid-19 vaccine for children between the ages of five and 11.

After more than seven hours of meeting, the experts of this advisory body gave the green light to the recommendation, with 17 votes in favor and one abstention.

The committee had to vote yes or no on the question of whether the benefits of Pfizer’s vaccine outweigh the risks in children between the ages of five and 11.

Now, the FDA will have to issue its own decision on the matter, which is expected by November 1, and later the Centers for Disease Control and Prevention (CDC, in English) will have to scrutinize the immunization of this age group.

The CDC’s own advisory committee is scheduled to meet Nov. 2-3 to review Pfizer vaccine data for children ages five to 11, before the agency’s director, Rochelle Walenksy, have the last word on it.

During Tuesday’s session, expert Hong Yang, Risk-Benefit Assessment Advisor for the FDA Office of Biostatistics and Epidemiology, discussed several possible scenarios for the evolution of the pandemic.

In all cases, the benefits of immunizing children “clearly” outweigh the risks, Yang said, citing myocarditis, an inflammation of the heart, as one of the possible dangers.

On this subject, the expert indicated that, although there is a theoretical risk of myocarditis in boys and that it is more present in vaccinated people, especially in young men, the benefits of being immunized seem to remain “strong”.



Read also

Leave a Reply

Your email address will not be published. Required fields are marked *